Biogen Alzheimer’s drug gets full FDA approval


The U.S. Food and Drug Administration has granted full, traditional approval to an Alzheimer's disease drug made by Eisai Inc. and Biogen Inc., six months after it won conditional approval from the same agency.

Previous Bi3's latest wave of grants includes $4.3M to support new TriHealth Center for Health Equity
Next Fast-growing Atlanta startup hires another new C-suite member